Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
Preclinical: A More Efficient and Selective Path to Anti-Cancer Drugs
/in Preclinical Research/by MaxA New Wave in Bone Grafting: Coral-Inspired Material Offers Hope for Faster Healing
/in Preclinical Research/by MaxActivating GP130 Protein Shows Promise in Prostate Cancer Treatment
/in Preclinical Research/by MaxPromising Results for B7-H3 Antibody-Drug Conjugate in Advanced Solid Tumors (including metastatic castration resistant prostate cancer)
/in Clinical Trial, Metastatic, Phase 1/by MaxAPVO442: A Promising New Bispecific Antibody for Prostate Cancer Treatment
/in Preclinical Research/by MaxMetformin Shows Promise in Reducing Side Effects of Hormone Therapy in Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxJanux Therapeutics Announces 100% Response in Phase 1a Results for JANX007 in mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxCopper Deprivation: A Novel Anti-Cancer Strategy
/in Preclinical Research/by Max